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med.unipi.itAbstractWe investigated the prevalence of normocalcemic primary hyperparathyroidism (NPHPT) in
the adult population living in a village in Southern Italy. All residents in 2010 (nZ2045) were
invited by calls and 1046 individuals accepted to participate. Medical history, calcium intake,
calcium, albumin, creatinine, parathyroid hormone (PTH) and 25OHD were evaluated.
NPHPT was defined by normal albumin-adjusted serum calcium, elevated plasma PTH, and
exclusion of common causes of secondary hyperparathyroidism (SHPT) (serum 25OHD
!30 ng/ml, estimated glomerular filtration rate (eGFR)!60 ml/min per 1.73 m2 and thiazide
diuretics use), overt gastrointestinal and metabolic bone diseases. Complete data were
available for 685 of 1046 subjects. Twenty subjects did not meet the inclusion criteria and 341
could not be evaluated because of thawing of plasma samples. Classical PHPTwas diagnosed
in four women (0.58%). For diagnosing NPHPT the upper normal limit of PTH was
established in the sample of the population (nZ100) who had 25OHDR30 ng/ml and eGFR
R60 ml/min per 1.73 m2 and was set at the meanC3S.D. Three males (0.44%) met the
diagnostic criteria of NPHPT. These subjects were younger and with lower BMI than those
with classical PHPT. Our data suggest, in line with previous studies, that NPHPT might be a
distinct clinical entity, being either an early phenotype of asymptomatic PHPT or a distinct
variant of it. However, we cannot exclude that NPHPT might also represent an early phase of
non-classical SHPT, since other variables, in addition to those currently taken into account
for the diagnosis of NPHPT, might cumulate in a normocalcemic subject to increase
PTH secretion.Key Words
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onEndocrine Connections
(2015) 4, 172–178IntroductionDuring the past 10–20 years several investigators have
noticed that there are patients with elevated serum
parathyroid hormone (PTH) levels associated with con-
sistently normal serum calcium concentration and no
other causes of secondary hyperparathyroidism (SHPT),and they described this entity as normocalcemic primary
hyperparathyroidism (NPHPT) (1, 2, 3). This entity can
only be recognized if PTH is measured in normocalcemic
individuals. Vitamin D deficiency/insufficiency, the most
common cause of SHPT, should be first to be excluded insed under a Creative Commons
Commercial 4.0 International License.
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such renal failure, hypercalciuria, gastrointestinal diseases
associated with malabsorption and other metabolic bone
diseases that could affect PTH levels (e.g. Paget’s disease)
should be excluded. Finally, the use of medications which
might affect PTH levels or calcium metabolism (estrogens,
thiazide diuretics, lithium, bisphosphonates, denosumab
and anticonvulsants) should also be ruled out (4).
Few data are available on the prevalence of NPHPT,
and most information has been obtained from subjects
undergoing evaluation for skeletal health or selected
populations (5, 6, 7).
The aim of the present study was to investigate the
prevalence of NPHPT in the adult population living in
a small village in Southern Italy.Subjects and methods
The survey was conducted in the late summer of 2010 in
Pescopagano, a village in Southern Italy, together with
a study on the prevalence of thyroid disorders (8). All
residents registered in 2010 (nZ2045) were invited by
two consecutive calls and 1046 adults participated in the
study (Fig. 1). Informed consent was obtained from all
participants.
All subjects underwent a medical interview, focused
on their medical history, the use of calcium, vitamin D
supplementation and anti-osteoporotic dugs. Daily
calcium intake was estimated using a self-administered
questionnaire (9).
Quantitative ultrasound scanning (QUS) at calcaneus
was performed using a Hologic Sahara device (Hologic,
Bedford, MA, USA). Speed-of-sound (SOS, in m/s) and
broadband ultrasound attenuation (BUA, in dB/MHz) and
stiffness index were calculated.
Blood samples were obtained by venipuncture and
serum and plasma aliquots were stored at K20 8C.
Serum calcium, albumin and creatinine were
measured using standard methods. Albumin-adjusted
total serum calcium (alb-sCa) was calculated (10); the
normal range was 8.6–10.2 mg/dl. Plasma PTH was
measured by the Liason N-Tact PTH II (DiaSorin, Inc.,
Sitllwater, MN, USA); the intra-assay and inter-assay
coefficient of variation (CV) at 10 pg/ml (lower normal
value of the kit) and 65 pg/ml (upper normal value) were
7.2 and 4.0%, and 10.8 and 6.2%, respectively. Serum
25OHD was measured by RIA (DiaSorin, Inc.); the intra-
assay and inter-assay CV at 10 and 30 ng/ml were 8.1 and
10.1%, and 7.8 and 9.0%, respectively. Vitamin D
sufficiency was defined by serum 25OHD levelshttp://www.endocrineconnections.org
DOI: 10.1530/EC-15-0030
 2015 The Authors
Published by Bioscientifica LtdR30 ng/ml, as suggested by the Endocrine Society (11)
and several opinion leaders (12, 13). Previous studies have
shown that plasma PTH starts to raise when serum 25OHD
concentration is below this value (14, 15). The estimated
glomerular filtration rate (eGFR) was evaluated from
serum creatinine (16).
The diagnosis of PHPT was based on increased alb-sCa,
associated with elevated or inappropriately normal intact
PTH. The diagnosis of NPHPT was based on the finding
of normal alb-sCa and abnormally increased plasma PTH
levels – the upper normal limit was calculated as detailed
below – provided that serum 25OHD concentration was
R30 ng/ml and the eGFR R60 ml/min per 1.73 m2 and
that subjects did not have overt gastrointestinal and
metabolic bone diseases nor were taking thiazide diuretics.Statistical analysis
All comparative analyses were performed with an inten-
tion-to-treat approach. Normality was assessed using the
Shapiro–Wilk test, histograms and Q–Q plots. Continuous
variables were expressed as means and S.D. Between-group
differences were evaluated using the independent-samples
t-test or ANOVA for continuous variables and the c2 test or
Fisher’s exact test for categorical variables, as appropriate.
All P values were two-tailed and the minimum level of
statistical significance was set at P!0.05. Statistical
analyses were performed with the use of SAS software,
version 8.2 (SAS Institute, Cary, NC, USA).Results
The study group consisted of 1046 adult subjects (642
women, 404 men; mean age 48.2G17.4, median 48.0,
range 18–89 years) (Fig. 1). Complete medical and
biochemical data were available in 685 subjects (66.8%);
ultrasound studies were missing in 46 of them. Herein we
refer to this sample of subjects as ‘fully evaluated’ (Fig. 1).
This cohort included 419 women and 266 men. The
age did not differ between women and men. This cohort
was comparable in terms of age and gender with the 1026
fully evaluated subjects. The complete biochemical and
QUS evaluation is reported in Table 1.
Four women (0.58%) had classic hypercalcemic PHPT
and 581 had SHPT (Fig. 1, Table 2).
We focused the following studies on the remaining
100 subjects, who had normal alb-sCa, serum 25OHD
R30 ng/ml and/or eGFR R60 ml/min per 1.73 m2, in
order to identify those with abnormally elevated plasma
PTH, namely the subjects who will meet the diagnosticThis work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
Invited (n=2045)
Accepted to
participate (n=1148)
Evaluated (n=1046)
Excluded by medical history (n=20)
Fully investigated (n=1026)
• Bisphosphonates (n=13)
• Daily calcium intake questionnaire
• Blood sampling
• Calcaneus quantitative ultrasound scanning 
• Thiazide diuretics (n=2)
• Pregnancy (n=2)
• Chronic renal failure (n=3)
Did not respond (n=897)
Not evaluated: 102 subjects
aged <18 years
Fully evaluated (n=685)
Not further evaluated because of thawing of
plasma samples for PTH assay (n=341)
Normal 25OHD (≥30 ng/ml) and eGFR ≥60
ml/min per 1.73 m2 (n=100)
• 25OHD <30 ng/ml and eGFR <60 ml/min per 1.73 m2 (n=43)
• eGFR <60 ml/min per 1.73 m2 (n=7)
• 25OHD <30 ng/ml (n=531)
Primary hyperparathyroidism (n=4)
Secondary hyperparathyroidism (n=581)
Subjects with normal calcium and PTH (n=97)
Normocalcemic primary hyperparathyroidism (n=3)
Figure 1
Diagram of the study population and evaluation. Plasma PTH levels were normally distributed in these 100 subjects; the upper limit of the normal range of
plasma PTH was set at the meanC3S.D.
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Table 1 Characteristics of fully evaluated subjects and subgroups of subjects with normal 25OHD (R30 ng/ml) and normal eGFR
(R60 ml/min per 1.73 m2) and secondary hyperparathyroidism.
Parameter
Fully evaluated
(nZ685)
Secondary
hyperparathyroidism
(nZ581)a
Normal 25OHD
and eGFR
(nZ100)
Age (years) 47.6G17.4 48.2G17.3 43.2G17.6
Sex
Female pre-MP 262 221 40
Female post-MP 157 138 16
Male 266 222 44
BMI (kg/m2) 27.8G5.2 28.1G5.3 26.2G4.3
Estimated daily calcium intake (mg) 754G472 755G486 763G403
eGFR (ml/min per 1.73 m2) 94.6G30.0 94.9G30.6 92.3G22.5
Alb-sCa (mg/dl) 9.1G0.5 9.0G0.5 9.1G0.3
Plasma PTH (pg/ml) 68.2G35.1 68.9G33.9 58.9G23.1
Serum 25OHD (ng/ml) 20.3G10.5 17.4G7.6 37.9G7.7
Calcaneal USb
SOS (m/s) 1527G41 1526G41 1533G35
BUA (dB/MHz) 67.3G20.4 67.0G20.9 69.3G17.0
Stiffness index 82.5G24.4 82.1G24.8 84.9G21.7
Pre-MP, premenopausal; post-MP, postmenopausal; eGFR, estimated glomerular filtration rate; alb-sCa, albumin-adjusted serum calcium; SOS, speed of
sound; BUA, broadband ultrasound attenuation.
aFour patients had primary hyperparathyroidism.
bData were available in 639 subjects.
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normal PTH range is of paramount importance. Plasma
PTH levels were normally distributed in these 100 subjects,
and we decided to set the upper normal limit at the
meanC3S.D. Contrary to what could be expected when
values are normally distributed, three subjects, all males,
had plasma PTH levels above this cut-off value (and
therefore met the diagnostic criteria of NPHPT. Thus, the
prevalence rate of NPHPT was three out of 685 (0.44%).Table 2 Characteristics of subjects with normocalcemic primary hy
and controlsa.
ID Sex Age (years) BMI (kg/m2)
Estima
daily cal
intake (
Normocalcemic primary hyperparathyroidism (nZ3)
FM M 21 21.0 669
MM M 56 27.3 107
FS M 64 28.3 1205
MeanGS.D. 47.0G22.9 25.5G3.9 660G5
Hypercalcemic primary hyperparathyroidism (nZ4)
MA F 86 25.8 428
GL F 52 24.0 160
MP F 68 36.2 508
AC F 59 30.0 857
MeanGS.D. 66.2G14.7 29.0G5.4 488G2
Controls (nZ97)
MeanGS.D. 43.1G17.1 26.2G4.4 748G3
eGFR, estimated glomerular filtration rate; alb-sCa, albumin-adjusted serum ca
aControls are subjects with normal alb-sCa and PTH, 25OHDR30 ng/ml and eGF
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Published by Bioscientifica LtdThe clinical and biochemical parameters of the three
subjects with NPNPT are reported in Table 2 together with
those of the four patients with classical PHPT and normal
controls.Discussion
NPHPT is a new clinical entity identified by the widespread
use of PTH assay in the evaluation of skeletal health,perparathyroidism, hypercalcemic primary hyperparathyroidism
ted
cium
mg)
eGFR (ml/min
per 1.73 m2)
alb-sCa
(mg/dl)
Plasma PTH
(pg/ml)
Serum 25OHD
(ng/ml)
90.9 8.9 130 37.4
73.7 8.8 131 32.2
125 8.9 139 42.8
49 96.5G26.1 8.9G0.1 133G5 37.5G5.3
124.5 10.6 119 19.4
109.6 10.5 130 21.2
68.0 10.8 167 6.5
79.3 11.1 382 14.8
87 95.3G26.2 10.7G0.2 199G123 15.5G6.6
95 90G21.3 9.1G0.3 58.9G23.1 37.9G7.7
lcium.
R R60 ml/min per 1.73 m2.
This work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
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5–7 4 :176particularly in postmenopausal women (4). This con-
dition, characterized by elevated PTH levels and normal
total and ionized serum calcium, and no other causes of
SHPT, can only be recognized by measuring PTH in
normocalcemic individuals (4).
The epidemiology of NPHPT has been investigated in
various populations (5, 6, 7). Most studies were performed
in selected gender and age groups, and different diagnostic
criteria were used. Moreover, not all causes of SHPT were
excluded. Finally, with the exception of the study of
Lundgren et al. (7), ionized calcium was not measured.
Therefore, the available data might overestimate the true
prevalence of NPHPT.
In the present study the evaluation of the prevalence
of NPHPT in an unselected sample of the whole
community of adults living in a small village in Southern
Italy (nZ685 (37.2%)) could give a more accurate estimate
of the true prevalence of NPHPT. The key points in
addressing this issue are to exclude all secondary causes of
elevated PTH levels and to define the upper limit of
normal plasma PTH. The upper normal limit of PTH is
usually fixed at the 97.5th percentile; therefore, some
individuals with slightly elevated PTH might be wrongly
classified as NPHPT. The novelty of our study is that we
defined the upper normal limit of PTH in the same
population in which we performed the study and that it
was set at the meanC3S.D. (99th percentile). The choice of
the meanC3S.D. for defining the upper normal PTH level
makes it unlikely that we classified as NPHPT normal
subjects. According to this criterion, the estimated
prevalence of NPHPT in our series was three out of 685
(0.44%) subjects. If we adopted the most commonly
approach of 2S.D. (97.5th percentile) for defining the
upper normal limit of PTH five subject instead of three
would have been classified as NPHPT, leading to a
prevalence of 0.73%.
The prevalence of NPHPT in our study is lower than
that reported by Cusano et al. (6) (3.1%) in an unselected
population-based cohort (Dallas Hearth Study), despite
the use of a lower cut-off value of 25OHD (R20 ng/ml). In
another population-based study (Canadian Multicenter
Osteoporosis Study) Berger et al. found a greater preva-
lence (16.7%), using the same cut-off value of serum
25OHD (R20 ng/ml), but not excluding other causes of
SHPT (17). However, if in the latter population the
analysis is limited to subjects whose 25OHD was
O30 ng/ml, the prevalence of NPHPT falls to 6.9%, a
figure closer to that found by Cusano et al. (6) but
definitely higher that that found in our study. Other
studies in selected populations have shown a prevalence ofhttp://www.endocrineconnections.org
DOI: 10.1530/EC-15-0030
 2015 The Authors
Published by Bioscientifica LtdNPHPT ranging between 0.4 and 6% (5, 6, 7, 18).
Differences in age, gender, ethnicity and criteria to
exclude SHPT may account for these findings.
All patients with NPHPT were males. A similar but not
significantly different gender distribution was reported by
Cusano et al. (6). Conversely, no gender difference was
observed by Berger et al. (19).
A regular monitoring of subjects with NPHPT is
advisable. Indeed, some may remain stable for years with
persistently elevated plasma PTH levels and normal
serum calcium, whereas others may progress to a
classical form PHPT, with development of hypercalcemia
and target organ involvement (6, 20, 21). Conversely, as
shown by Cusano et al., a significant proportion of
subjects with provisional diagnosis of NPHPT would no
longer fit this diagnosis during follow-up. As a matter of
fact, upon retesting after approximately 8 years, 64 of
the 108 subjects initially classified as NPHPT, only 13
(20%) continued to show biochemical findings of
NPHPT, 20 no longer met the NPHPT criteria because
of other causes of SHPT, one developed hypercalcemic
PHPT, one showed hypercalcemia in the setting of renal
failure, and 29 had normal PTH (6). Therefore, the
prevalence of NPHPT fell from 3.1 to 0.6% of the total
cohort with follow-up data. The latter finding under-
scores the need for biochemical monitoring of patients
with a provisional diagnosis of NPHPT in order to
confirm the diagnosis.
We would like to add a word of caution when
evaluating a subject with a suspected NPHPT based upon
established criteria (1, 6): other variables which may
increase PTH secretion (which are not currently taken
into account for the diagnosis of NPHPT), such as age,
BMI, waist circumference, calcium intake, subclinical
gastrointestinal disorders, etc. might cumulate in an
individual patient to trigger hyperparathyroidism. There-
fore, the possibility that NPHPT may represent an early
phase of non-classical SHPT cannot be excluded. Thus, in
borderline cases retesting after vitamin D and calcium
supplementation may be advisable. Finally, the use of an
oral peptone and calcium load test might be useful in
selected cases to differentiate patients with NPHPT from
those with PHPT (22).
Our study has some limitations: i) the entire adult
village population was not investigated; ii) complete
information regarding the current medical therapy was
unavailable in few patients; iii) ionized serum calcium and
urinary calcium excretion were not measured; iv) a single
blood sample was drawn from each participating subjectThis work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
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data were available.
We were unable to measure ionized serum calcium
and 24-h urinary calcium excretion, which are important
parameters for a secure diagnosis of NPHPT. As far as
ionized serum calcium is concerned, we recognize that,
although there is in general a linear relationship between
albumin-corrected serum calcium and ionized calcium,
some discrepancies may occur (23). However we believe
that this should not be the case in our three subjects
classified as NPHPT, because their albumin-corrected
serum calcium was well below the upper normal limit,
and this never occur in our clinical practice. We did not
measure 24-h urinary calcium because we thought that it
would have been very difficult to collect reliable 24-h urine
sample in a population study like the present one.
However, it is of note that all previous studies on the
prevalence of NPHPT in the various populations so far
reported did not include the measurement of this
parameter. Finally, missing the diagnosis of familial
hypocalciuric hypercalcemia (FHH) in our population
would be insignificant due to the very low prevalence of
FHH (1:10 000–1:100 000) (24).
Our study has the strength that we evaluated a
population-based adult cohort, which included both
females and males, and collected data on calcaneus
ultrasound scanning. To our knowledge only two other
studies have evaluated similar cohorts and in only one
study was bone mineral density measured. Moreover, the
normal range of plasma PTH was established in the same
population studied, and a more conservative criterion of
abnormally increased plasma PTH value (corresponding to
the 99.7 percentile) was used.
In conclusion, despite the limitations mentioned
above, our data provide further support for the recog-
nition of NPHPT as a new clinical entity, which may be
either an early phenotype of asymptomatic PHPT or a
distinct variant of it. However, we cannot exclude that the
biochemical findings suggestive of NPHPT might also
represent an early phase of non-classical SHPT, since other
variables, in addition to those currently taken into
account for the diagnosis of NPHPT, might cumulate in
a normocalcemic subject to increase PTH secretion. Long-
term follow-up studies of subjects with biochemical
finding of NPHPT are needed to shed light on these issues.Declaration of interest
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